The FDA has broadened Arexvy’s approved age range to include adults 18–49 at higher risk of severe RSV — providing earlier protection against this serious respiratory virus.
🔗
https://www.medscape.com/viewarticle/fda-approves-expanded-age-indication-rsv-vaccine-2026a100083z
#FDAAlert #HealthNews 🌿
MedscapeFDA Approves Expanded Age Indication for RSV Vaccine
The FDA has approved expanded use of Arexvy, an RSV vaccine, for those aged 18-49 at increased LRTD risk.
